Lucinda Steward

This inventor holds 24 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Hoffmann-La Roche Inc.. Active years: 2008-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lucinda Steward. Retrieved from https://idiyas.com/inventor/lucinda-steward

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 3)

% Patents Active = 12.5

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

24 out of 5,026

Hoffmann-La Roche Inc.

patents

Years Active: 2008-2014

Loading Chart...

Areas of Expertise:

Quinolines

2-Aminoquinolines

Benzoxazines

Dopamine Receptor Modulators

Benzoyl-Piperidine Derivatives

D3 Receptor

5-HT2A Receptor

Isoxazolo[4,5]Pyridin

4-Alkyl-3,4-Dihydro-Quinazolin

Ether Derivatives

Piperazine Derivatives

Dihydro-Quinazolin

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8829029 - [object Object] (2014-09-09),

2. 8415350 - [object Object] (2013-04-09),

3. 8399674 - Quinolines (2013-03-19),

4. 8350028 - 2-aminoquinolines (2013-01-08),

5. 8188284 - 2-aminoquinolines (2012-05-29),

6. 8183380 - 2-aminoquinolines (2012-05-22),

7. 8163740 - 6-substituted benzoxazines (2012-04-24),

8. 8097637 - Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors (2012-01-17),

9. 8044047 - 5-substituted benzoxazines (2011-10-25),

10. 8039490 - Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors (2011-10-18),

11. 7994324 - 2-aminoquinoline derivatives (2011-08-09),

12. 7989628 - 2-aminoquinolines (2011-08-02),

13. 7939535 - Benzo[D]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors (2011-05-10),

14. 7923561 - Quinolines (2011-04-12),

15. 7858630 - [object Object] (2010-12-28),

Title: Lucinda Steward: Innovator in CNS Disorders Treatment

Introduction

Lucinda Steward is a notable inventor based in Basel, Switzerland, recognized for her significant contributions to medical science through her innovative work in pharmacology. With a remarkable portfolio of 24 patents, she has made strides in the development of compounds aimed at treating various central nervous system (CNS) disorders.

Latest Patents

Among her recent patents, Lucinda has developed compounds that function as dual modulators of serotonin 5-HT and dopamine D receptors. These compounds are particularly promising for the treatment of psychotic disorders, as well as other conditions such as depression, anxiety, drug dependence, dementias, and memory impairment. Her inventive approach leverages unique chemical formulations, ensuring effective therapeutic outcomes for patients suffering from these complex psychological conditions.

Career Highlights

Lucinda is currently employed at Hoffmann-La Roche Inc., a leading global healthcare company engaged in research and development of pharmaceuticals and diagnostics. Throughout her career, she has played a pivotal role in advancing the field of psychiatric treatment through her inventions, showcasing her ability to combine scientific expertise with practical applications in medicine.

Collaborations

In her journey as an inventor, Lucinda has collaborated with esteemed colleagues, including Sabine Kolczewski and Luca Claudio Gobbi. Together, they have contributed to groundbreaking research that enhances healthcare solutions and exemplifies the spirit of teamwork in scientific discovery.

Conclusion

Lucinda Steward stands out as a visionary inventor whose work in pharmacology is instrumental in addressing significant health challenges related to CNS disorders. Her innovative spirit is reflected in her extensive patent portfolio and collaborative efforts, marking her as a key figure in the medical innovation landscape. As she continues to push the boundaries of science, her contributions will undoubtedly pave the way for improved therapeutic strategies and better outcomes for patients worldwide.

Profile summary based on public USPTO records.